Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma

被引：0

作者：

Dummer, R. ^{[1
]}

Ascierto, P. A. ^{[2
]}

Gogas, H. ^{[3
]}

Arance, A. ^{[4
]}

Mandala, M. ^{[5
]}

Liszkay, G. ^{[6
]}

Garbe, C. ^{[7
]}

Schadendorf, D. ^{[8
]}

Krajsova, I. ^{[9
,10
]}

Gutzmer, R. ^{[11
]}

Sileni, V. Chiarion ^{[12
]}

Dutriaux, C. ^{[13
]}

de Groot, J. W. B. ^{[14
]}

Yamazaki, N. ^{[15
]}

Loquai, C. ^{[16
]}

de Parseval, L. A. ^{[17
]}

Pickard, M. ^{[18
]}

Sandor, V. ^{[19
]}

Robert, C. ^{[20
]}

Flaherty, K. T. ^{[21
]}

机构：

[1] Univ Hosp Zurich Dermatol, Dept Dermatol, Zurich, Switzerland

[2] Ist Nazl Tumori Fdn Pascale, Unit Melanoma Canc Immunotherapy & Innovat Therap, Naples, Italy

[3] Natl & Kapodestrian Univ Athens, Laikon Hosp, Dept Internal Med, Athens, Greece

[4] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[5] Papa Giovanni XXIII Canc Ctr Hosp, Dept Oncol & Haematol, Bergamo, Italy

[6] Natl Inst Oncol, Dept Dermatol, Budapest, Hungary

[7] Eberhard Karls Univ Tubingen, Div Dermatooncol, Dept Dermatol, Tubingen, Germany

[8] Univ Hosp Essen, Dept Dermatol, Heidelberg, Germany

[9] Univ Hosp Prague, Dept Dermatooncol, Prague, Czech Republic

[10] Charles Univ Prague, Med Fac 1, Prague, Czech Republic

[11] Hannover Med Sch, Dept Dermatol & Allergy, Skin Canc Ctr, Hannover, Germany

[12] Oncol Inst Veneto IRCCS, Melanoma Canc Unit, Padua, Italy

[13] Hop St Andre, Dept Oncol Dermatol, Ctr Hosp Univ Bordeaux, Bordeaux, France

[14] Dept Med Oncol, Isala, Zwolle, Netherlands

[15] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan

[16] Univ Med Ctr, Dept Dermatol, Mainz, Germany

[17] Novartis Pharma AG, Translat Clin Oncol, Basel, Switzerland

[18] Array BioPharma Inc, Biostat & Data Management, Boulder, CO USA

[19] Array BioPharma Inc, Med Affairs, Boulder, CO USA

[20] Inst Gustave Roussy, Dept Med, Villejuif, France

[21] Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1215O

引用

页数：2

共 50 条

[1] Results of COLUMBUS Part 2: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus ENCO in BRAF - Mutant Melanoma
Dummer, Reinhard
Ascierto, Paolo A.
Gogas, Helen J.
Arance, Ana
Mandala, Mario
Liszkay, Gabriella
Garbe, Claus
Schadendorf, Dirk
Krajsovÿ, Ivana
Gutzmer, Ralf
Sileni, Vanna Chiarion
Dutriaux, Caroline
de Groot, Jan Willem B.
Yamazaki, Naoya
Loquai, Carmen
de Parseval, Laure A.
Pickard, Michael
Sandor, Victor
Berking, Carola
Robert, Caroline
Flaherty, Keith T.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 12 - 13
[2] Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma
Arance, A.
Dummer, R.
Ascierto, P. A.
Gogas, H.
Mandala, M.
Liszkay, G.
Garbe, C.
Schadendorf, D.
Krajsova, I.
Gutzmer, R.
Sileni, V. Chiarion
Dutriaux, C.
de Groot, J. W. B.
Yamazaki, N.
Loquai, C.
de Parseval, L. A.
Pickard, M.
Sandor, V.
Robert, C.
Flaherty, K. T.
ANNALS OF ONCOLOGY, 2017, 28
[3] Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma
Dummer, Reinhard
Ascierto, Paolo Antonio
Gogas, Helen
Arance, Ana M.
Mandala, Mario
Liszkay, Gabriella
Garbe, Claus
Schadendorf, Dirk
Krajsova, Ivana
Gutzmer, Ralf
Chiarion-Sileni, Vanna
Dutriaux, Caroline
de Groot, Jan Willem
Yamazaki, Naoya
Loquai, Carmen
De Parseval, Laure A.
Pickard, Michael D.
Sandor, Victor
Robert, Caroline
Flaherty, Keith
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[4] Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma
Gogas, H.
Dummer, R.
Ascierto, P. A.
Arance, A.
Mandala, M.
Liszkay, G.
Garbe, C.
Schadendorf, D.
Krajsova, I.
Gutzmer, R.
Sileni, V. Chiarion
Dutriaux, C.
de Groot, J. W. B.
Yamazaki, N.
Loquai, C.
de Parseval, L. A.
Pickard, M.
Sandor, V.
Robert, C.
Flaherty, K. T.
ANNALS OF ONCOLOGY, 2017, 28
[5] Quality-of-Life (QoL) in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma
Berking, Carola
Ascierto, Paolo A.
Gogas, Helen J.
Arance, Ana
Mandala, Mario
Liszkay, Gabriella
Garbe, Claus
Schadendorf, Dirk
Krajsova, Ivana
Gutzmer, Ralf
Sileni, Vanna Chiarion
Dutriaux, Caroline
de Groot, Jan Willem B.
Yamazaki, Naoya
Loquai, Carmen
de Parseval, Laure A.
Pickard, Michael
Sandor, Victor
Robert, Caroline
Flaherty, Keith T.
Dummer, Reinhard
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 45 - 45
[6] Overall Survival (OS) in COLUMBUS: A Phase-III-Study with Encorafenib (ENCO) plus Binimetinib (BINI) versus Vemurafenib (VEM) or ENCO in BRAF mutant Melanoma
Dummer, R.
Ascierto, P. A.
Gogas, H. J.
Arance, A.
Mandala, M.
Liszkay, G.
Garbe, C.
Schadendorf, D.
Krajsova, I
Gutzmer, R.
Chiarion-Sileni, V
Dutriaux, C.
de Groot, J. W. B.
Yamazaki, N.
Loquai, C.
Moutouh-de Parseval, L. A.
Pickard, M. D.
Sandor, V
Robert, C.
Flaherty, K. T.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 41 - 41
[7] Update on overall survival in COLUMBUS: A randomised phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma
Haydon, Andrew
Liszkay, Gabriella
Gogas, Helen J.
Mandala, Mario
Arance, Ana
Garbe, Claus
Dummer, Reinhard
Ascierto, Paolo A.
Robert, Caroline
Pickard, Michael D.
Sandor, Victor
Gollerkeri, Ashwin
Flaherty, Keith T.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 171 - 172
[8] Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.
Gogas, Helen
Ascierto, Paolo Antonio
Flaherty, Keith
Arance, Ana
Mandala, Mario
Liszkay, Gabriella
Garbe, Claus
Schadendorf, Dirk
Krajsova, Ivana
Gutzmer, Ralf
de Groot, Jan Willem
Dutriaux, Caroline
Loquai, Carmen
Gollerkeri, Ashwin
Pickard, Michael D.
Robert, Caroline
Dummer, Reinhard
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.
Liszkay, Gabriella
Gogas, Helen
Mandala, Mario
Fernandez, Ana Maria Arance
Garbe, Claus
Schadendorf, Dirk
Dummer, Reinhard
Ascierto, Paolo Antonio
Robert, Caroline
Pickard, Michael D.
Sandor, Victor
Gollerkeri, Ashwin
Flaherty, Keith
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[10] 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) plus binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma
Dummer, R.
Flaherty, K. T.
Robert, C.
Arance, A.
De Groot, J. W. B.
Garbe, C.
Gogas, H. J.
Gutzmer, R.
Krajsova, I.
Liszkay, G.
Loquai, C.
Mandala, M.
Schadendorf, D.
Yamazaki, N.
Zohren, F.
Edwards, M.
Ascierto, P. A.
ANNALS OF ONCOLOGY, 2021, 32 : S872 - S873

← 1 2 3 4 5 →